Press Releases from InDex Pharmaceuticals (7 total)
InDex Pharmaceuticals Granted Japanese Patent for Novel Treatment of Steroid-Res …
Stockholm, October 24, 2012 – InDex Pharmaceuticals today announced that it has been granted a Japanese patent by the Japan Patent Office (JPO). The patent provides protection for the use of Kappaproct® and other DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema, and chronic obstructive pulmonary disease.
The patent, entitled “Immunostimulatory Method” covers the use of a broad range…
Kappaproct Drastically Reduces the Need for Colectomy in Patients with Severe Ul …
- InDex Pharmaceuticals reports positive clinical data in peer-reviewed journal Inflammatory Bowel Diseases -
Stockholm, June 19, 2012 – InDex Pharmaceuticals today announced the publication of positive data from the Company's compassionate use program with its lead compound Kappaproct. In the program, eight treatment-refractory ulcerative colitis (UC) patients that had been elected for colectomy received Kappaproct, a DNA-based immunomodulatory sequence (DIMS) targeting the toll-like receptor 9 (TLR9).
The findings showed that…
InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member
- Former Lundbeck Executive Brings Strong Commercial Experience and Extensive Pharmaceutical Industry Network -
Stockholm, May 29, 2012 – InDex Pharmaceuticals today announced that Stig Løkke Pedersen has been appointed as a new member of the Board of Directors. Mr. Pedersen brings to InDex Pharmaceuticals over 25 years of longstanding life sciences industry experience in commercial operations and leadership.
Mr. Pedersen previously served as Executive Vice President of Commercial Operations at…
InDex Pharmaceuticals Granted US Patent for Novel Treatment of Steroid-Resistant …
Stockholm, April 26, 2012 – InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.
The patent, entitled “Method for Modulating Responsiveness to Steroids”…
InDex Pharmaceuticals Expands Management Team
- InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer -
Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced two additions to its management team: Pernilla Sandwall has been appointed as Head of Clinical Operations and Thomas Knittel as Chief Medical Officer. Pernilla Sandwall will lead the company’s clinical development team, with the main focus being the ongoing phase III clinical trial of Kappaproct®…
InDex Pharmaceuticals Develops Companion Diagnostic Test for New Ulcerative Coli …
- Personalized treatment option for patients with refractory ulcerative colitis -
Stockholm, March 20, 2012 - InDex Pharmaceuticals today announced the development of a companion diagnostic test for Kappaproct®. Kappaproct, the lead product candidate of InDex, is currently in a phase III study as a treatment for chronic active, treatment refractory ulcerative colitis. In this study, the companion diagnostic test is being evaluated to demonstrate a correlation between test result and…
InDex Pharmaceuticals Starts Phase III COLLECT Study with Kappaproct®
-- TLR9 Agonist for the Treatment of Chronic, Active, Treatment-Refractory Ulcerative Colitis --
Stockholm, March 6, 2012 - InDex Pharmaceuticals today announced the start of the COLLECT trial, a European multicenter Phase III study to evaluate the effectiveness and safety of Kappaproct for the treatment of chronic active ulcerative colitis (UC) patients not responding to available therapy. Kappaproct is a DNA-based immunomodulatory sequence (DIMS) targeting the toll-like receptor 9 (TLR9).
UC is…
